SARS-CoV-2-IN-14 (compound 6) 是一种有效的SARS-CoV-2抑制剂，IC50为 0.39 μM。SARS-CoV-2-IN-14 是一种氯硝柳胺类似物。SARS-CoV-2-IN-14 在人血浆和肝 S9 酶测定中比氯硝柳胺具有更高的稳定性，口服给药可提高生物利用度和半衰期。

SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC 50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally [1].

22203-98-1

C13H9Cl2NO2

282.12

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years